Profile data is unavailable for this security.
About the company
Zhejiang Ausun Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of specialty bulk pharmaceutical chemicals (BPCs) and pharmaceutical intermediates. The Company's main products include bimatoprost, latanoprost, latanoprostene bunod, entecavir, selectfluor and other intermediates. The Company is also involved in the provision of customized production, as well as research and development services to customers through its subsidiaries.
- Revenue in CNY (TTM)855.13m
- Net income in CNY272.71m
- Incorporated2010
- Employees1.17k
- LocationZhejiang Ausun Pharmaceutical Co LtdNo. 5, Donghai 4th Avenue, Linhai ParkChemcial Raw Materials Pharmaceutical BaTAIZHOU 317016ChinaCHN
- Phone+86 57 685589367
- Fax+86 57 685589367
- Websitehttps://www.ausunpharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Orient Gene Biotech Co Ltd | 627.03m | -414.61m | 5.47bn | 2.23k | -- | 0.7436 | -- | 8.73 | -2.05 | -2.05 | 3.11 | 36.51 | 0.065 | 0.9281 | 2.10 | 281,055.40 | -4.58 | 29.62 | -5.53 | 38.29 | 43.94 | 59.69 | -70.46 | 35.82 | 4.27 | -- | 0.0767 | 19.24 | -90.65 | 23.46 | -119.23 | -- | 121.04 | -- |
| Zhejiang Ausun Pharmaceutical Co Ltd | 855.13m | 272.71m | 5.96bn | 1.17k | 21.83 | 2.63 | -- | 6.97 | 0.4604 | 0.4604 | 1.44 | 3.82 | 0.2876 | 1.21 | 3.71 | 728,389.90 | 9.17 | 9.38 | 12.29 | 12.84 | 54.14 | 53.09 | 31.89 | 27.14 | 1.96 | -- | 0.1592 | 23.53 | 6.83 | 27.35 | 7.87 | 42.07 | 24.32 | 50.50 |
| Shandong Lukang Pharmaceutical Co Ltd | 6.28bn | 267.79m | 6.28bn | 6.48k | 23.97 | 1.70 | -- | 1.00 | 0.292 | 0.292 | 6.88 | 4.11 | 0.7187 | 3.54 | 6.45 | 967,865.70 | 3.21 | 2.21 | 5.51 | 4.05 | 23.55 | 23.41 | 4.47 | 3.46 | 0.7313 | 5.39 | 0.4689 | 31.79 | 9.34 | 13.04 | 78.37 | 8.81 | -16.95 | 23.94 |
| Cisen Pharmaceutical Co Ltd | 4.48bn | 528.35m | 6.31bn | 3.40k | 11.98 | 1.07 | -- | 1.41 | 1.16 | 1.16 | 9.86 | 13.02 | 0.6082 | 2.81 | 5.65 | 1,315,959.00 | 7.21 | 6.94 | 9.02 | 8.56 | 57.33 | 56.27 | 11.85 | 10.77 | 3.12 | -- | 0.0373 | 33.42 | 9.75 | 3.22 | 48.92 | 0.697 | -15.19 | 10.72 |
| JiangSu WuZhong Pharmactcl Devlpm Co Ltd | 2.33bn | -95.04m | 6.38bn | 1.05k | -- | 3.61 | -- | 2.74 | -0.1335 | -0.1335 | 3.22 | 2.48 | 0.553 | 16.07 | 2.29 | 2,220,525.00 | -2.31 | -2.92 | -4.78 | -5.30 | 22.41 | 28.14 | -4.18 | -5.77 | 1.22 | -0.3232 | 0.5063 | -- | 10.55 | 5.65 | 5.58 | -- | -19.08 | -- |
Data as of Jun 28 2024. Currency figures normalised to Zhejiang Ausun Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
1.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Jun 2024 | 1.59m | 0.27% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 1.08m | 0.18% |
| Caitong Fund Management Co., Ltd.as of 30 Jun 2023 | 847.91k | 0.14% |
| CCB Principal Asset Management Co., Ltd.as of 31 Dec 2023 | 800.08k | 0.14% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 573.52k | 0.10% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 493.09k | 0.08% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2023 | 478.10k | 0.08% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 413.67k | 0.07% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 356.76k | 0.06% |
| HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 292.50k | 0.05% |
More ▼
Data from 30 Jun 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
